199 related articles for article (PubMed ID: 20307255)
1. Pharmacological properties of thalidomide and its analogues.
De Sanctis JB; Mijares M; Suárez A; Compagnone R; Garmendia J; Moreno D; Salazar-Bookaman M
Recent Pat Inflamm Allergy Drug Discov; 2010 Jun; 4(2):144-8. PubMed ID: 20307255
[TBL] [Abstract][Full Text] [Related]
2. Properties of thalidomide and its analogues: implications for anticancer therapy.
Teo SK
AAPS J; 2005 Mar; 7(1):E14-9. PubMed ID: 16146335
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulatory properties of thalidomide analogs: pomalidomide and lenalidomide, experimental and therapeutic applications.
Bodera P; Stankiewicz W
Recent Pat Endocr Metab Immune Drug Discov; 2011 Sep; 5(3):192-6. PubMed ID: 21913886
[TBL] [Abstract][Full Text] [Related]
4. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.
Galustian C; Meyer B; Labarthe MC; Dredge K; Klaschka D; Henry J; Todryk S; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB; Dalgleish AG
Cancer Immunol Immunother; 2009 Jul; 58(7):1033-45. PubMed ID: 19009291
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo.
Reddy N; Hernandez-Ilizaliturri FJ; Deeb G; Roth M; Vaughn M; Knight J; Wallace P; Czuczman MS
Br J Haematol; 2008 Jan; 140(1):36-45. PubMed ID: 17995965
[TBL] [Abstract][Full Text] [Related]
6. Lenalidomide - current understanding of mechanistic properties.
Tageja N
Anticancer Agents Med Chem; 2011 Mar; 11(3):315-26. PubMed ID: 21426296
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory drugs as a therapy for multiple myeloma.
De Raeve H; Vanderkerken K
Curr Pharm Biotechnol; 2006 Dec; 7(6):415-21. PubMed ID: 17168657
[TBL] [Abstract][Full Text] [Related]
8. Thalidomide and lenalidomide in the treatment of multiple myeloma.
Kumar S; Rajkumar SV
Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621
[TBL] [Abstract][Full Text] [Related]
9. The thalidomide saga.
Melchert M; List A
Int J Biochem Cell Biol; 2007; 39(7-8):1489-99. PubMed ID: 17369076
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide analogs as emerging anti-cancer drugs.
Dredge K; Dalgleish AG; Marriott JB
Anticancer Drugs; 2003 Jun; 14(5):331-5. PubMed ID: 12782937
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory drugs in multiple myeloma.
Zangari M; Elice F; Tricot G
Expert Opin Investig Drugs; 2005 Nov; 14(11):1411-8. PubMed ID: 16255679
[TBL] [Abstract][Full Text] [Related]
12. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells.
Marriott JB; Clarke IA; Dredge K; Muller G; Stirling D; Dalgleish AG
Clin Exp Immunol; 2002 Oct; 130(1):75-84. PubMed ID: 12296856
[TBL] [Abstract][Full Text] [Related]
13. [Immunomodulatory effects of lenalidomide].
Handa H; Saitoh T; Murakami H
Nihon Rinsho; 2015 Jan; 73(1):156-61. PubMed ID: 25626322
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide derived immunomodulatory drugs (IMiDs) as potential therapeutic agents.
Marriott JB; Dredge K; Dalgleish AG
Curr Drug Targets Immune Endocr Metabol Disord; 2003 Sep; 3(3):181-6. PubMed ID: 12871024
[TBL] [Abstract][Full Text] [Related]
15. Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomide.
Henry JY; Labarthe MC; Meyer B; Dasgupta P; Dalgleish AG; Galustian C
Immunology; 2013 Jul; 139(3):377-85. PubMed ID: 23374145
[TBL] [Abstract][Full Text] [Related]
16. IMiDs: a novel class of immunomodulators.
Knight R
Semin Oncol; 2005 Aug; 32(4 Suppl 5):S24-30. PubMed ID: 16085014
[TBL] [Abstract][Full Text] [Related]
17. Recent advances of IMiDs in cancer therapy.
Li S; Gill N; Lentzsch S
Curr Opin Oncol; 2010 Nov; 22(6):579-85. PubMed ID: 20689431
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.
Quach H; Ritchie D; Stewart AK; Neeson P; Harrison S; Smyth MJ; Prince HM
Leukemia; 2010 Jan; 24(1):22-32. PubMed ID: 19907437
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulatory drugs.
Crane E; List A
Cancer Invest; 2005; 23(7):625-34. PubMed ID: 16305990
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKC-theta activation and enhancing the DNA-binding activity of AP-1 but not NF-kappaB, OCT-1, or NF-AT.
Payvandi F; Wu L; Naziruddin SD; Haley M; Parton A; Schafer PH; Chen RS; Muller GW; Hughes CC; Stirling DI
J Interferon Cytokine Res; 2005 Oct; 25(10):604-16. PubMed ID: 16241859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
